[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623964":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":31,"responsibleParty":51,"collaborators":18,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":18,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":76,"whyStopped":18,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nīmes","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"combined use of mPCR and algorithm-based therapy","EXPERIMENTAL","strategy combining respiratory mPCR on a deep respiratory sample obtained by mini bronchoalveolar lavage and algorithm-based therapy developed using local epidemiology",[13],"Procedure: strategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology",{"label":15,"type":16,"description":17,"interventionNames":18},"Conventional strategy for antibiotic therapy at discretion of ICU physicians","NO_INTERVENTION","The conventional strategy is based on the clinician's choice in accordance with best practice recommendations, without the combined use of respiratory mPCR and algorithm-based therapy.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"PROCEDURE","strategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology","strategy combining respiratory mPCR carried out either by mini bronchoalveolar lavage (BAL) via bronchoscopy or by blind mini BAL, and algorithm-based therapy developed using local epidemiology for the early optimization of initial antibiotic therapy",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Hugo MARTINIERE, PH","CONTACT","+33 4 66 68 33 31","hugo.martiniere@chu-nimes.fr",[32],{"facility":33,"status":18,"city":34,"state":18,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"CHU Nîmes","Nîmes","34070","France","FR",{"type":39,"coordinates":40},"Point",[41,42],4.35788,43.83665,{"lat":42,"lon":41},[45,48],{"name":46,"role":28,"phone":47,"phoneExt":18,"email":30},"Hugo Martiniere, PH","+ 33 6 68 68 33 31",{"name":49,"role":50,"phone":18,"phoneExt":18,"email":18},"Hugo Martiniere, MD","PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100623964","phase-4-combined-use-of-a-respiratory-multiplex-pcr-and-algorithm-based-therapy-to-improve-early-optimization-of-antibiotic-therapy-in-critically-ill-patients-with-ventilator-associated-pneumonia-100623964",false,"NCT07403474","Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Therapy in Critically Ill Patients With Ventilator-associated Pneumonia","Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Therapy in Critically Ill Patients With Ventilator-associated Pneumonia : a Bicentric, Parallel-group, Randomized Controlled Trial.","SMART-VAP","Inclusion Criteria:\n\n* Adults (≥18 years) with VAP (mechanical ventilation and hospitalization ≥ 48 hours) and deep respiratory sample by mini BAL \\\u003C 12 hours. The diagnosis of pneumonia includes two clinical criteria among fever (≥38.3°C), purulent sputum or aspiration, hyperleukocytosis (\\>12,000 WBC\u002Fmm³) or leukopenia (\\\u003C4,000 WBC\u002Fmm³), hypoxemia, auscultatory signs in the affected area, and a newly-appeared parenchymal infiltrate\n* Patient receiving initial probabilistic antibiotic therapy for VAP suspicion\n* Informed consent or emergency procedure\n* Patient affiliated with or beneficiary of a health insurance plan.\n\nNon inclusion Criteria:\n\n* Pregnancy\n* Congenital immunodeficiency;\n* HIV infection with the lymphocyte CD4 count below 200\u002Fmm3 or unknown in the last year;\n* Acute hematologic malignancy;\n* Neutropenia (\\\u003C1 leucocyte\u002FmL or \\\u003C 0.5 neutrophil\u002FmL);\n* Immunosuppressive drugs within the previous 30 days, including anti-cancer - Chemotherapy and anti-rejection drugs for organ\u002Fbone marrow transplant\n* Corticosteroids ≥ 20 mg\u002Fd of prednisone equivalent for more than 14 days\n* Known allergy to beta-lactams\n* Moribund patient or death expected from underlying disease during the current admission;\n* Patient deprived of liberty or under legal protection measure;\n* Participation in another interventional trial.\n\nExclusion criteria :\n\n* mPCR non available","ALL","18 Years",{"count":64,"type":65},124,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","Assess the impact of a strategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology on the early optimization of initial antibiotic therapy for ventilator-associated pneumonia (VAP) (intervention), compared to a conventional strategy (control).\n\nA bicentric, parallel-group, randomized controlled trial. The primary assessment criterion is the proportion of early optimized antibiotic therapy within 24 hours of respiratory sampling.",[71],"Ventilator Associated Pneumonia ( VAP)",[73,74,75],"mPCR","ventilator associated pneumonia","algorithm-based therapy","NOT_YET_RECRUITING","2026-02-11",{"date":79,"type":80},"2026-02-12","ACTUAL",{"date":82,"type":65},"2026-06-01",{"date":84,"type":65},"2026-07-31",{"name":5,"class":6},1]